BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05732831 (TNG462 in MTAP-deleted Solid Tumors): BVCT ex-ante prediction vs. reported outcome

On 28 Jul 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 6 Nov 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially probably sufficient.

Clinical Trial

NCTID
NCT05732831
Drug Name
TNG462
Drug MoA
selective MTAP-mull-cell-specific PRMT5 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
MTAP-deleted Solid Tumors
Human Patients
159
Sponsor
Tango Therapeutics
Phase
Phase 1 Phase 2

Prediction of , index 1018

Prospective Prediction
Prediction Index
1018
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit in OS)
Technical Prediction
SUCCESS (statistically significant clinical benefit in ORR/PFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
101 days in advance
Readout Data Interpretation
TNG462 achieved 43% ORR for relapsed/refractory cholangiocarcinoma; superior to 5% ORR achieved by second-line chemotherapy for advanced biliary tract cancer; including cholangiocarcinoma (Lancet DOI- 10.1016/S1470-2045(21)00027-9)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially probably sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Phase
Phase 1, Phase 2
Status
Recruiting
Enrollment
225
Lead sponsor
Tango Therapeutics, Inc.
Conditions
Locally Advanced Solid Tumor
Interventions
DRUG: TNG462; DRUG: Pembrolizumab
Design
Non randomized · Sequential · None
Primary purpose
Treatment
Start
2023-05-26
Primary completion
2027-06
Completion
2028-06
Primary outcomes
  • Phase 1 Maximum Tolerated Dose (28 days and 21 days)
  • Phase 1 Dosing Schedule (28 days)
  • Phase 2 Anti-neoplastic Activity (16 weeks and 18 weeks)

NCT05732831 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials